Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Lexicon Pharmaceuticals Inc's Business Segments
Lexicon Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 21
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 21 | 100% |
Revenue by Product & Service Category - Q1 FY2026
- License94.8%
- Product5.2%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| License | $ 20 | 94.8% |
| Product | $ 1 | 5.2% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals Inc is a biopharmaceutical company that is focused on the discovery, development, and commercialization of innovative therapies for the treatment of various diseases. The company's mission is to improve patient lives by bringing breakthrough medicines to market.
The company was founded in 1995 and is headquartered in The Woodlands, Texas. It has a team of experienced professionals who have a track record of success in drug discovery and development, regulatory affairs, and commercialization.
Lexicon Pharmaceuticals has a diverse pipeline of drug candidates that are being developed for the treatment of various conditions such as diabetes, neuropathic pain, carcinoid syndrome, and irritable bowel syndrome. One of their most advanced drug candidates is sotagliflozin, which is a dual inhibitor of sodium-glucose cotransporter 1 and It is being developed as an adjunct to insulin therapy for type 1 diabetes and as a monotherapy for type 2 diabetes.
Another key drug candidate is telotristat etiprate, which is the first and only FDA-approved treatment for carcinoid syndrome diarrhea. The drug is also being developed for the treatment of refractory carcinoid syndrome and pulmonary arterial hypertension.
In addition to its robust pipeline of drug candidates, Lexicon Pharmaceuticals has strategic collaborations with pharmaceutical and biotech companies such as Sanofi, Ipsen, and Bristol-Myers Squibb. These collaborations provide additional resources and expertise to help the company advance its drug candidates and bring them to market.
Overall, Lexicon Pharmaceuticals is a well-established biopharmaceutical company with a strong commitment to developing innovative treatments for patients with unmet medical needs. Its strong pipeline and strategic collaborations position the company for continued growth and success in the future.
The company was founded in 1995 and is headquartered in The Woodlands, Texas. It has a team of experienced professionals who have a track record of success in drug discovery and development, regulatory affairs, and commercialization.
Lexicon Pharmaceuticals has a diverse pipeline of drug candidates that are being developed for the treatment of various conditions such as diabetes, neuropathic pain, carcinoid syndrome, and irritable bowel syndrome. One of their most advanced drug candidates is sotagliflozin, which is a dual inhibitor of sodium-glucose cotransporter 1 and It is being developed as an adjunct to insulin therapy for type 1 diabetes and as a monotherapy for type 2 diabetes.
Another key drug candidate is telotristat etiprate, which is the first and only FDA-approved treatment for carcinoid syndrome diarrhea. The drug is also being developed for the treatment of refractory carcinoid syndrome and pulmonary arterial hypertension.
In addition to its robust pipeline of drug candidates, Lexicon Pharmaceuticals has strategic collaborations with pharmaceutical and biotech companies such as Sanofi, Ipsen, and Bristol-Myers Squibb. These collaborations provide additional resources and expertise to help the company advance its drug candidates and bring them to market.
Overall, Lexicon Pharmaceuticals is a well-established biopharmaceutical company with a strong commitment to developing innovative treatments for patients with unmet medical needs. Its strong pipeline and strategic collaborations position the company for continued growth and success in the future.
Lexicon Pharmaceuticals Inc. is a pioneering biopharmaceutical company that emphasizes the development of innovative treatments aimed at addressing chronic diseases, primarily in the realms of diabetes, cardiovascular health, and oncology. Below is an extensive overview of the segments, products, and services offered by the company.
Segments
1. Diabetes
Lexicon Pharmaceuticals invests heavily in research and development targeted at diabetes management. The company is known for its groundbreaking work on various drug classes, including:
- SGLT1/SGLT2 Inhibitors: These inhibitors work by preventing the reabsorption of glucose in the kidneys, effectively lowering blood sugar levels. This category of drugs holds promise for patients with both type 1 and type 2 diabetes, with efforts aimed at enhancing blood glucose control and minimizing the dangers associated with the disease.
- Glucagon Receptor Antagonists: These agents are designed to block the action of glucagon, a hormone that raises blood glucose levels. By antagonizing glucagon, Lexicon aims to provide additional support for glucose control, particularly in patients who struggle with persistent hyperglycemia despite other treatments.
- Dual GIP/GLP-1 Agonists: By targeting multiple pathways involved in glucose metabolism, these dual agonists aim to improve insulin secretion, enhance glucose-dependent insulin release, and promote satiety, helping to manage both glucose levels and weight in diabetic patients.
Focus on diabetes research not only includes drug discovery but also entails understanding disease pathology for better therapeutic strategies.
Cardiovascular Health
Lexicon’s portfolio extends to addressing key aspects of cardiovascular health, including:
- Dyslipidemia: The company is committed to developing therapies aimed at correcting abnormal lipid levels. High cholesterol remains a significant risk factor for cardiovascular disease, and effective management is crucial.
- Hypertension: Lexicon is involved in creating medications to lower blood pressure, thereby reducing the risk of stroke and other cardiovascular complications.
- Heart Failure: Novel approaches targeting heart failure mechanisms are being explored, particularly the role of hormonal and metabolic factors in heart function. Researching ways to improve heart muscle performance and overall cardiac health remains a priority.
The lead product candidate in this segment is sotagliflozin, which is under development as an add-on treatment for type 1 diabetes and is expected to provide additional cardiovascular benefits.
Immunology/Oncology
Lexicon Pharmaceuticals recognizes the increasing need for advanced therapies in cancer and chronic inflammatory diseases. Its initiatives in this segment include:
- Oral Small Molecule Drugs: The focus here is on developing small molecule therapeutics that can be administered orally, targeting pathways associated with inflammation, immune responses, and tumor progression. These drugs are being designed to harness precision medicine approaches—tailoring treatments to the specific needs of patients based on the molecular characteristics of their diseases.
- Innovative Treatments for Chronic Inflammatory Diseases: By exploring novel avenues to modulate immune responses, Lexicon aims to offer solutions that can address conditions such as autoimmune diseases and chronic inflammation, which have significant overlaps with oncology.
Products
1. XERMELO (telotristat ethyl)
XERMELO is an approved medication that functions as an oral serotonin synthesis inhibitor. It is specifically indicated for treating carcinoid syndrome diarrhea in patients with metastatic neuroendocrine tumors (mNETs). By inhibiting serotonin production, it helps alleviate one of the more debilitating aspects of this syndrome, thereby improving the quality of life for patients.
Zynquista (sotagliflozin)
Zynquista is an oral dual SGLT1 and SGLT2 inhibitor that is being researched as an adjunct treatment for patients with type 1 diabetes. By targeting both the gastrointestinal and renal pathways involved in glucose regulation, Zynquista aims to assist in achieving better glycemic control when combined with insulin therapy.
Services
In addition to its product development efforts, Lexicon Pharmaceuticals offers a comprehensive suite of services to support the progression of new therapies:
- Clinical Development Services: These services include designing, managing, and executing clinical trials that test the safety and efficacy of new drugs. Expertise in trial design increases the likelihood of successful outcomes and regulatory approvals.
- Regulatory Strategy and Submission Support: Lexicon assists in navigating the complex regulatory landscape to ensure that new therapies meet all the requirements for approval by health authorities. This includes preparing submission documents and facilitating communication with regulatory bodies.
- Collaborations and Partnerships: Lexicon engages with other pharmaceutical and biotech companies through licensing agreements and research partnerships. This collaborative approach fosters innovation and accelerates the development of new treatments by leveraging external expertise and resources.
Conclusion
Lexicon Pharmaceuticals Inc. demonstrates a strong commitment to addressing significant medical needs in chronic disease management through its diverse range of segments, innovative products, and robust services. With a focus on diabetes and cardiovascular health, alongside its pioneering work in immunology and oncology, Lexicon continues to position itself as a leader in the biopharmaceutical landscape. Their comprehensive strategy fosters advancements in treatment modalities while aiming for improved patient outcomes.
Segments
1. Diabetes
Lexicon Pharmaceuticals invests heavily in research and development targeted at diabetes management. The company is known for its groundbreaking work on various drug classes, including:
- SGLT1/SGLT2 Inhibitors: These inhibitors work by preventing the reabsorption of glucose in the kidneys, effectively lowering blood sugar levels. This category of drugs holds promise for patients with both type 1 and type 2 diabetes, with efforts aimed at enhancing blood glucose control and minimizing the dangers associated with the disease.
- Glucagon Receptor Antagonists: These agents are designed to block the action of glucagon, a hormone that raises blood glucose levels. By antagonizing glucagon, Lexicon aims to provide additional support for glucose control, particularly in patients who struggle with persistent hyperglycemia despite other treatments.
- Dual GIP/GLP-1 Agonists: By targeting multiple pathways involved in glucose metabolism, these dual agonists aim to improve insulin secretion, enhance glucose-dependent insulin release, and promote satiety, helping to manage both glucose levels and weight in diabetic patients.
Focus on diabetes research not only includes drug discovery but also entails understanding disease pathology for better therapeutic strategies.
Cardiovascular Health
Lexicon’s portfolio extends to addressing key aspects of cardiovascular health, including:
- Dyslipidemia: The company is committed to developing therapies aimed at correcting abnormal lipid levels. High cholesterol remains a significant risk factor for cardiovascular disease, and effective management is crucial.
- Hypertension: Lexicon is involved in creating medications to lower blood pressure, thereby reducing the risk of stroke and other cardiovascular complications.
- Heart Failure: Novel approaches targeting heart failure mechanisms are being explored, particularly the role of hormonal and metabolic factors in heart function. Researching ways to improve heart muscle performance and overall cardiac health remains a priority.
The lead product candidate in this segment is sotagliflozin, which is under development as an add-on treatment for type 1 diabetes and is expected to provide additional cardiovascular benefits.
Immunology/Oncology
Lexicon Pharmaceuticals recognizes the increasing need for advanced therapies in cancer and chronic inflammatory diseases. Its initiatives in this segment include:
- Oral Small Molecule Drugs: The focus here is on developing small molecule therapeutics that can be administered orally, targeting pathways associated with inflammation, immune responses, and tumor progression. These drugs are being designed to harness precision medicine approaches—tailoring treatments to the specific needs of patients based on the molecular characteristics of their diseases.
- Innovative Treatments for Chronic Inflammatory Diseases: By exploring novel avenues to modulate immune responses, Lexicon aims to offer solutions that can address conditions such as autoimmune diseases and chronic inflammation, which have significant overlaps with oncology.
Products
1. XERMELO (telotristat ethyl)
XERMELO is an approved medication that functions as an oral serotonin synthesis inhibitor. It is specifically indicated for treating carcinoid syndrome diarrhea in patients with metastatic neuroendocrine tumors (mNETs). By inhibiting serotonin production, it helps alleviate one of the more debilitating aspects of this syndrome, thereby improving the quality of life for patients.
Zynquista (sotagliflozin)
Zynquista is an oral dual SGLT1 and SGLT2 inhibitor that is being researched as an adjunct treatment for patients with type 1 diabetes. By targeting both the gastrointestinal and renal pathways involved in glucose regulation, Zynquista aims to assist in achieving better glycemic control when combined with insulin therapy.
Services
In addition to its product development efforts, Lexicon Pharmaceuticals offers a comprehensive suite of services to support the progression of new therapies:
- Clinical Development Services: These services include designing, managing, and executing clinical trials that test the safety and efficacy of new drugs. Expertise in trial design increases the likelihood of successful outcomes and regulatory approvals.
- Regulatory Strategy and Submission Support: Lexicon assists in navigating the complex regulatory landscape to ensure that new therapies meet all the requirements for approval by health authorities. This includes preparing submission documents and facilitating communication with regulatory bodies.
- Collaborations and Partnerships: Lexicon engages with other pharmaceutical and biotech companies through licensing agreements and research partnerships. This collaborative approach fosters innovation and accelerates the development of new treatments by leveraging external expertise and resources.
Conclusion
Lexicon Pharmaceuticals Inc. demonstrates a strong commitment to addressing significant medical needs in chronic disease management through its diverse range of segments, innovative products, and robust services. With a focus on diabetes and cardiovascular health, alongside its pioneering work in immunology and oncology, Lexicon continues to position itself as a leader in the biopharmaceutical landscape. Their comprehensive strategy fosters advancements in treatment modalities while aiming for improved patient outcomes.